share_log
Benzinga ·  Apr 25 16:56
INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Neuroinflammation
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment